Inovio Pharmaceuticals (INO) Convertible Debt (2019 - 2022)
Inovio Pharmaceuticals (INO) posted Convertible Debt of $16.6 million for Q4 2022, up 1.92% sequentially from $16.3 million in Q3 2022, and up 11.06% YoY from $15.0 million in Q4 2021.
Inovio Pharmaceuticals (INO) Convertible Debt (2019 - 2022) Analysis & Trends
Inovio Pharmaceuticals has reported Convertible Debt for 4 years, with the latest figure at $16.6 million in Q4 2022.
- Quarterly Convertible Debt rose 11.06% year-over-year to $16.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $16.6 million (up 11.06% YoY) and the FY2022 annual result came in at $16.6 million, up 11.06% from the prior year.
- Convertible Debt rose to $16.6 million in Q4 2022 per INO's latest filing, from $16.3 million in the prior quarter.
- Over five years, Convertible Debt peaked at $65.8 million in Q2 2020 and troughed at $4.2 million in Q3 2020.
- A 4-year average of $28.8 million and a median of $16.3 million in 2022 frame the typical range for Convertible Debt.
- The sharpest annual moves came in 2020 and 2021: Convertible Debt sank 93.32% in 2020, then soared 231.27% in 2021.
- Over 4 years, Convertible Debt stood at $64.2 million in 2019, then tumbled by 92.96% to $4.5 million in 2020, then jumped by 231.27% to $15.0 million in 2021, then grew by 11.06% to $16.6 million in 2022.
- According to Business Quant data, Convertible Debt over the past three periods registered $16.6 million, $16.3 million, and $16.5 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 95.90 Mn | 95.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 16.61 Mn |
| Sep 30, 2022 | 16.30 Mn |
| Jun 30, 2022 | 16.52 Mn |
| Mar 31, 2022 | 16.21 Mn |
| Dec 31, 2021 | 14.96 Mn |
| Jun 30, 2021 | 14.54 Mn |
| Mar 31, 2021 | 14.07 Mn |
| Dec 31, 2020 | 4.52 Mn |
| Sep 30, 2020 | 4.15 Mn |
| Jun 30, 2020 | 65.84 Mn |
| Mar 31, 2020 | 63.73 Mn |
| Dec 31, 2019 | 64.18 Mn |
| Sep 30, 2019 | 62.12 Mn |